Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Investor Presentation (January 2024)
25 slides from Palisade Bio's investor presentation, January 2024
Slide 1: Transforming the Treatment of GI Diseases
palisadebio.com NASDAQ CM: PALI Transforming the Treatment of GI Diseases Corporate Presentation January 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and pre-clinical and clinical development plans, expected near and long
Slide 3: Investment Highlights
Investment KEY HIGHLIGHTS Recent transaction jumpstarts into Highlights high-value IBD market Clinically validated PDE4 target utilized Developing novel therapeutics for by multiple Big Pharma players serious chronic gastrointestinal Rapidly advancing towards Phase 1 initiation diseases, with a targ
Slide 4: Our Oral IBD Development Pipeline
Our Oral IBD Development Pipeline Oral Prodrug Therapies that Act Locally at Site of Disease IND/CTA- Program Discovery Phase 1 Phase 2 Phase 3 Highlights Enabling Ongoing IND/CTA-enabling tox studies PALI-2108 Ulcerative Colitis Rapidly advancing towards IND/CTA filing in 2024 Lead optimization com
Slide 5: Strategic Shift in Prioritization to Newly Licensed Assets for Treatment of IBD
Strategic Shift in Prioritization to Newly Licensed Assets for Treatment of Inflammatory Bowel Diseases We entered into an exclusive worldwide licensing agreement to develop and commercialize proprietary oral prodrug therapies that act locally targeting multi-billion-dollar IBD market Company Secure
Slide 6: Big Pharma is Active in IBD and Spending Big Dollars for Earlier Stage Programs
Big Pharma is Active in IBD and Spending Big Dollars for Earlier Stage Programs Company Acquirer Date Lead Asset Phase at Deal MOA Upfront Total Deal Royalties Current Status Anti-TL1A Oct 2023 RVT-3101 Phase 3 Ready Mab $7.1 Billion $7.2 Billion NA Phase 3 Prep Anti-TL1A Oct 2023 TEV'574 Phase 2b M
Slide 7: Inflammatory Bowel Diseases (IBD)
Inflammatory Bowel Diseases (IBD) Chronic Condition Characterized by Persistent Inflammation in the Digestive Tract Diagnosed in Early Adulthood with Alternating Periods of Activity and Remission Symptoms COLITIS Diarrhea CROHN’S Abdominal pain Fatigue Cramping Blood in your stool Reduced appetite F
Slide 8: IBD is a Large and Growing Market
IBD is a Large and Growing Market 2,3 CURRENT IBD MARKET Expected to Grow 1 to $20B by 2031 Ulcerative Colitis Crohn’s Disease Novel Therapeutics Demonstrating Safety and Efficacy are Likely to Gain Market Share 1.95 Million 1.63 Million Cases Cases Palisade Bio Has the Only PDE4 Under Development f
Slide 9: The IBD Patient Journey
ULCERATIVE COLITIS Of patients have moderate-to-severely ~40-50% The IBD active disease Of patients with active disease will 70% Patient Journey have active disease the next year Of patients in remission will have 30% active disease the next year Of patients with long-lasting UC and Patients and cli
Slide 10: Current Standard-of-Care Therapies Have Limited Effectiveness
Current Standard-of-Care Therapies Have Limited Effectiveness No Standard Regimen for Managing All IBD Patients The Approach to Treatment Needs to Be Tailored for the Individual CURRENT FACTORS THAT DETERMINE TREATMENT APPROACH TREATMENT APPROACH 5-ASA is generally first line for ulcerative colitis
Slide 11: PALI-2108: Targeting Ulcerative Colitis
PALI-2108 Targeting Ulcerative Colitis 11
Slide 12: Ulcerative Colitis Competitive Landscape
Ulcerative Colitis Competitive Landscape Most Effective Therapies Have Black Box Warning, New Therapies Are Not as Effective Placebo-Adjusted Overall Remission Route of Safety Drug Company Indication FDA Approval Clinical Remission Rate Administration Considerations Moderate-to-severely active UC wi
Slide 13: Potential Future Ulcerative Colitis Competitive Landscape
Potential Future Ulcerative Colitis Competitive Landscape UC Market is Expected to Evolve By 2028 with New Therapies We Believe PALI-2108 Has a Significant Advantage Over Current Projections and has Potential to Take Significant Market Share Placebo-Adjusted Overall Remission Route of Safety Drug Co
Slide 14: Our Differentiated Approach to Ulcerative Colitis
PALI-2108: Our Differentiated Approach to Ulcerative Colitis Novel PDE4 Inhibitor Pre-IND/CTA Candidate Oral Prodrug Therapies That Act Locally at Site of Disease KEY DIFFERENTIATION Oral Dosing Locally Active Limited Systemic Activity (improved safety) Superior Cytokine Blocking Profile P
Slide 15: PALI-2108: Mechanism of Action
BAL DELIVERY PALI-2108: Mechanism of Action — 2 * a ode Ht > See lendritic cell enzyme * = BIOACTIVATION PALI-2108 PALI-0008 _| SUPERIOR TNF-« ‘PDE4 INHI ITOR PRODRUG PDE4 INHIBITOR §| BLOCKING PROFILE : ns CAL ACTIVATION S = SS . -- Tell “~ > ee, a. = - Y ‘ ‘ashe. Monocyte . © immen systemic ft 7 4
Slide 16: PALI-2108 Data Highlights
PALI-2108 Data Highlights DSS Mouse Proof of Efficacy Study Exclusively selective for PDE4 limiting the potential for off-target effects Isoenzyme inhibition profile comparable to marketed DAI (% AUC) anti-inflammatory and anti-fibrotic PDE4 inhibitor 20 times more potent as a TNFα inhibitor than
Slide 17: PDE4 is an Established Dual Acting Anti-Inflammatory and Anti-Fibrotic Target
PDE4 is an Established Dual Acting (Pleiotropic) Anti-Inflammatory and Anti-Fibrotic Target COPD (Roflumilast; AstraZeneca): Anti-fibrotic indications such as chronic obstructive pulmonary disease Psoriasis and Psoriatic Arthritis (Apremilast; Amgen): Anti- inflammatory indications validated by appr
Slide 18: Demonstrated High Potential for Locally Acting PDE4
Demonstrated High Potential for Locally Acting PDE4 Two Placebo-Controlled Randomized Trials Have Been Conducted Mild-to-Moderate Moderate-to-Severely Active UC1 Active UC2 Significant improvement in disease activity index (DAI) at Week 8 Significant improvement in clinical remission rate of 19.2% S
Slide 19: PALI-2108 Development Plan Through Phase 1a/b
PALI-2108 Development Plan Through Phase 1a/b Q2 Q3 Q4 Q1 Q2 Q3 Q4 H1 H2 2023 2023 2023 2024 2024 2024 2024 2025 2025 GMP Manufacturing IND/CTA-enabling Studies Regulatory Interactions IND/CTA Submission Phase 1a/b Initiation of Ph1 a/b Clinical Study First Patient In Topline Data 19
Slide 20: Precision Medicine Approach
Precision Medicine Approach Precision Medicine Approach for Elevated express of PDE4 in chronic UC Selecting Patients Most Likely to patients correlates with disease activity by Mayo score1 Respond to PDE4 Therapy in UC Elevated expression of inflammatory PROTEOMICS cytokines has been shown in c
Slide 21: Significant IP Portfolio Through 2042
Significant IP Portfolio Through 2042 Composition of Matter Patent Family Composition of Matter PCT/CA2021/050725 Coverage Until 2042+ National Phase Entry of PCT FDA Regulatory Exclusivity December 2022 Coverage for 8 Years National Phase Entry Potential to File Additional Patents US, Canada, China
Slide 22: Program Team
Program Team JD Finley, MT Mitch Jones, MD, PhD Joie Bernard, PhD Adarsh Patel, MSc, BSc CEO CMO Translational Medicine, Technical Affairs Med Affairs Christophe Mellon, PhD Jon Daniels, PhD Patrick Colin, B. Pharm, PhD CMC & Medicinal Chemistry Safety & Tox & Reg (Consultant) Clinical Dev/Ops (Cons
Slide 23: Financial Snapshot
Financial Snapshot Strong Financial Position with Cash to Fund Operations into 2025 $15.3M ~$5M ~193K Cash Market Cap 1 Volume 1 As of September 30, 2023 23 1: As of January 24, 2024, with a closing price of $0.53 and total number of shares outstanding of 9,217,129
Slide 24: Investment Summary
Oral therapeutics addressing UC and CD in high-value IBD market Investment Growing body of data demonstrating locally Summary acting, locally acting approach improves efficacy and safety PDE4 target validated by multiple approved products Developing novel therapeutics for serious chronic gastrointes
Slide 25: Transforming the Treatment of GI Diseases
palisadebio.com NASDAQ CM: PALI Transforming the Treatment of GI Diseases Investor Relations: JTC Team, LLC 833-475-8247 PALI@jtcir.com